Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $26.0K $26.0K $701.0K $52.0K $207.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-5.3M $-1.3M $-1.0M $-1.0M $-469.0K $-1.3M $-973.0K
Operating Margin -5,103.8% -3,969.2% -66.9% -2,509.6% -470.0%
Interest Expense
Pretax Income $-3.4M $1.1M $1.2M $-386.0K $-462.0K $-1.3M $-973.0K
Income Tax Expense $19.0K $347.0K $-156.0K $-200.0K $7.0K $7.0K $6.0K
Net Income $-3.4M $778.0K $1.4M $-186.0K $-469.0K $-1.3M $-979.0K
Net Margin 2,992.3% -715.4% -66.9% -2,521.2% -472.9%
EPS (Basic) $-0.07 $-0.01 $0.00 $-0.02 $0.00 $0.00 $0.00
EPS (Diluted) $-0.07 $-0.01 $0.00 $-0.02 $0.00 $0.00 $0.00
Shares Outstanding (Basic) 14.3M 74.2M 74.2M 74.2M 74.2M 74.2M 51.1M 44.21B
Shares Outstanding (Diluted) 14.3M 74.2M 74.2M 74.2M 74.2M 74.2M 51.1M 44.21B
Dividends Per Share
← Newer Page 1 of 3 Older →